SKA2 and Alzheimer disease: Importantly, we were able to validate these findings in an independent replication cohort of PFC samples of AD cases (n = 40) and age matched controls (n = 37) (Supplementary Data 11), demonstrating significantly reduced SKA2 expression in AD (Fig. 7K, left), and thus pointing towards hyperactivated SA in AD.